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ABSTRACT
Selected circulating microRNAs (miRNAs) have been suggested for non-invasive 
screening of non-small cell lung cancer (NSCLC), however the numerous proposed 
miRNA signatures are inconsistent. 
Aiming to identify miRNAs suitable specifically for stage I-II NSCLC screening in 
serum/plasma samples, we searched the databases “Pubmed”, “Medline”, “Scopus”, 
“Embase” and “WOS” and systematically reviewed the publications reporting 
quantitative data on the efficacy [sensitivity, specificity and/or area under the curve 
(AUC)] of circulating miRNAs as biomarkers of NSCLC stage I and/or II. The 20 
studies fulfilling the search criteria included 1110 NSCLC patients and 1009 controls, 
and were of medium quality according to Quality Assessment of Diagnostic Accuracy 
Studies checklist. In these studies, the patient cohorts as well as the control groups 
were heterogeneous for demographics and clinicopathological characteristics; 
moreover, numerous pre-analytical and analytical variables likely influenced miRNA 
determinations, and potential bias of hemolysis was often underestimated. We 
identified four circulating miRNAs scarcely influenced by hemolysis, each featuring 
high sensitivity (> 80%) and AUC (> 0.80) as biomarkers of stage I-II NSCLC: miR-
223, miR-20a, miR-448 and miR-145; four other miRNAs showed high specificity 
(> 90%): miR-628-3p, miR-29c, miR-210 and miR-1244. In a model of two-step 
screening for stage I-II NSCLC using first the above panel of serum miRNAs with 
high sensitivity and high AUC, and subsequently the panel with high specificity, the 
estimated overall sensitivity is 91.6% and overall specificity is 93.4%. These and 
other circulating miRNAs suggested for stage I-II NSCLC screening require validation 
in multiple independent studies before they can be proposed for clinical application.
INTRODUCTION
Lung cancer is the most common cause of cancer 
death worldwide, globally accounting for an estimated 1.5 
million deaths in 2012 [1, 2]. In Europe, every year lung 
cancer causes about 353000 deaths, which represent nearly 
20% of total cancer deaths [3]. Approximately 15% of 
lung cancers are histologically classified as small cell lung 
cancer, a very aggressive and generally incurable tumor; 
the remaining 85% are cumulatively classified as Non-
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Small Cell Lung Cancer (NSCLC). The latter contains 
two main histological subtypes, adenocarcinoma (AC) and 
squamous cell carcinoma (SCC), and can often be cured if 
diagnosed at an early stage [4, 5].
 The five-year survival rate of lung cancer is low 
worldwide (10–15%), mainly because the majority of 
cases are diagnosed with advanced stage, when treatment 
is rarely curative. In the NSCLC cases that are diagnosed 
at an early stage (stage I and II), the five-year survival 
rate dramatically improves, ranging from 70% to 85% for 
surgically resected stage I disease [6], lobectomy being 
the established and most effective therapeutic approach 
[7]. However, less than one third of NSCLC cases are 
diagnosed in early stage [8–10] and the methodologies 
currently available for early diagnosis present several 
limitations. Chest X-rays have low sensitivity for lung 
cancer detection, whereas low-dose chest computed 
tomography (CT) scan has high sensitivity but low 
specificity [11–14]. The latter is a relevant limitation of CT 
scan for screening, considering that among individuals at 
risk for lung cancer (heavy smokers and former smokers) 
20–60% of chest CT exams show pulmonary nodules, the 
vast majority of which are eventually diagnosed as benign 
after completion of work up [15, 16]. Moreover, in many 
areas of the world chest CT is a rather expensive and not 
widely available screening tool [17].
Newer, minimally invasive and effective methods 
of screening for lung cancer are needed. MicroRNAs 
(miRNAs) are small non-protein-coding RNA molecules 
18–25 nucleotide long that play an important role in 
eukaryotic gene expression regulation. They have been 
shown to be dysregulated in human diseases, including 
cancer [18, 19]. The aberrant expression of specific 
miRNAs in body fluids from individuals with cancer has 
suggested their possible application as cancer biomarkers 
[20–25]. The quantification of selected miRNAs in plasma 
or serum of high risk individuals has been proposed as 
a simple and potentially effective screening tool for 
early detection of NSCLC. Unfortunately, the miRNA 
signatures identified by numerous published studies of 
lung cancer patients are largely inconsistent, the reported 
miRNA profiles being incoherent [23, 26–33]. These 
studies have been the subject of several reviews and 
meta-analyses [34–40]. However, these reviews were 
not focused on circulating miRNAs in cancer stage I and 
II, potentially amenable to radical cure. Moreover, the 
accuracy of miRNA quantification in plasma/serum is 
known to be affected by several methodological variables, 
including modality of sample preparation, hemolysis, 
RNA isolation procedures, method of cDNA preparation 
and method used for miRNA measurement. These factors, 
that likely contribute to the puzzling inconsistency of the 
published miRNA profiles of NSCLC, were only partially 
addressed in the aforementioned reviews. 
Here we aimed to review the literature in order to 
identify circulating miRNAs proven to be valuable and 
highly accurate for diagnosis of early NSCLC (stage I and 
II). Further, based on our analysis, we propose two panels 
of miRNAs for diagnosis of stage I-II NSCLC, with a two-
tier screening method.
RESULTS
Included studies
Our literature search identified a total of 1712 
articles, from which duplicates were removed, yielding 
1239 papers. After reviewing titles, abstracts and full 
texts, 17 papers fulfilling our search criteria were finally 
included. Manual search of the bibliography of these 
papers led to include 3 additional records, yielding a total 
of 20 articles (Figure 1). Among these, 8 papers studied 
single miRNAs only, 6 explored both single miRNAs and 
panels, and 6 focused on miRNA panels only. For the 20 
studies included in the review, Supplementary Table 1A 
indicates the main characteristics of patients and controls, 
and the investigated individual miRNAs or panels; 
Supplementary Table 1B provides information on methods 
used for miRNA quantification. 
The selected studies, all published in the years 
2011–2017, included 2119 individuals in total (1110 
NSCLC patients and 1009 controls). The sample size 
ranged between 11 and 126 for NSCLC cohorts and 
between 11 and 110 for controls. The median sample 
size was 56 patients (interquartile range 30–79) with 1.1 
case/control ratio. In all selected papers the sample mean 
age ranged 60–65 years, except in the study by Shi and 
colleagues that was carried out in a younger patient group 
(patient mean age, 50) [41]. 
Of the 20 studies (10 from China, 4 from USA, 
2 from Italy and 1 each from Poland, Norway, Russia 
and France), 8 were conducted on Caucasian patients (2 
studies included African American subjects), 7 on Asian 
patients and 5 did not provide information on ethnicity 
(Supplementary Table 1A). 
The NSCLC patient groups differed by 
clinicopathological status across the studies and some 
relevant data were missing. Regarding the patients’ 
smoking status and comorbidities, four studies did not 
report any data on smoking [41–44]; two studies included 
only smokers (with > 20 mean pack-years) [26, 30]; 
five studies included ≥ 85% of smokers among NSCLC 
patients [27, 29, 45–47]. Fourteen of the 20 studies 
provided no information on comorbidity of the patient 
cohort; the other 6 studies indicated that patients had no 
history of other cancers (Supplementary Table 1A) [26, 
48–52]. A mix of the two main subtypes of NSCLC, AC 
and SCC, was present in all the selected papers, however 
only in 11 studies the accuracy of the miRNA profile of 
NSCLC was separately evaluated for AC and SCC [26, 29, 
30, 41, 44, 46, 48–50, 53, 54]. The composition of control 
groups was also varied (Supplementary Table 1A). Four 
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studies [30, 44, 53, 55] provided no medical information 
on the control group. In 4 studies, history of no tumor and 
negative chest imaging (X-rays or CT scan) were used to 
identify healthy controls [26, 46, 47, 51]. In the other 12 
studies, individuals broadly defined “healthy subjects” or 
“non-neoplastic subjects” based on medical history, served 
as controls; 3 of these studies included patients with 
chronic obstructive pulmonary disease (COPD) [29, 45, 
47] and 4 studies included controls with benign pulmonary 
nodules or non-cancerous lung disease [45, 48, 50, 52]. 
miRNA extraction
miRNAs were extracted from serum samples in 10 
studies, from plasma samples in 9 studies, from whole 
blood in 1 study (Supplementary Table 1B). A training 
and a validation set were both described in 8 studies; of 
these, 4 reported two different procedures to quantify 
miRNAs in the training and validation sets. For miRNA 
extraction (Supplementary Table 1B), the mirVana PARIS 
RNA kit (Ambion, ThermoFisher) was used in 7 studies, 
the miRNeasy mini kit (Qiagen) in 3 studies, and in one 
study each the miRCURY RNA isolation kit (Exiqon), 
the RNA extraction kit (Applied Biosystems, AB), the 
NucleoSpin miRNA Plasma kit (Macherey-Nagel) were 
used. In the study by Yuxia et al. [42], RNA extraction 
was not performed, whereas 2 studies used phenol and 
guanidine isothiocyanate reagents only [27, 49]. Addition 
of spike-ins as a quality control step was reported in 5 
papers (Supplementary Table 1B). 
Figure 1: PRISMA flow diagram illustrating the study selection process. From the 1712 initially identified studies, duplicates 
were removed and records were screened by title, abstract, full text, leading to inclusion of 17 studies. Manual search of these papers led to 
inclusion of 3 further studies, for a total of 20 studies finally included in our review. aAmong completed studies, no protocol satisfying the 
inclusion criteria was retrieved. Protocols in the recruiting stage were excluded.
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miRNA retrotranscription and quantification
In 13 studies “Taqman” stem&loop primers and 
kits (AB) were used for retrotranscription, combined with 
two quantification methods [Taqman Low Density Arrays 
microRNA signature panel (TLDA, AB)] or another 
array -6 papers- and/or probe based relative quantitative 
PCR (qPCR) -12 papers-, as detailed in Supplementary 
Table 1B. Absolute miRNA quantification by Droplet 
Digital PCR (ddPCR) was performed in only 1 study, 
after retrotranscription with stem&loop primers [28]. In 
3 studies, qPCR based on intercalating dyes was used for 
miRNA quantification. In 3 studies insufficient details of 
the procedures were provided [29, 41, 48]; (Supplementary 
Table 1B). 
Normalization
As shown in Supplementary Table 1B, in the 
6 studies using TLDA for quantification, the data 
were normalized with a geometric mean of different 
miRNAs, or with global normalization, or with quantile 
normalization. In the 14 studies using qPCR quantification, 
a single endogenous reference molecule (miR-16 or U6) 
was used in 7 studies; 4 studies used means of at least 
two endogenous reference genes; 2 studies used a single 
exogenous spike-in; 1 study did not provide details about 
normalization [42] (Supplementary Table 1B).
Individual miRNAs
In the 20 selected studies, altogether 27 miRNAs 
were individually reported (Table 1). Overall the studies 
were of medium quality as assessed by Quality Assessment 
of Diagnostic Accuracy Studies (QUADAS-2) checklist, 
where “patient selection” and “index test” resulted the most 
critical domains. The diagnostic performance of individual 
miRNAs varied widely: sensitivity ranged between 30.4% 
and 96.1%, specificity between 38.2% and 100%; moreover, 
for some miRNAs (miR-223, miR-21, miR-145, miR-125b) 
the AUC differed substantially between independent studies 
(Table 1), suggesting that variability of patients, controls or 
methods may affect miRNA levels. 
Identification of highly sensitive and highly 
specific miRNAs 
Aiming to identify within Table 1 the individual 
miRNAs suitable for possible clinical application as 
non-invasive screening tool, we needed first to eliminate 
miRNAs influenced by hemolysis, a major source of bias. 
Therefore, we decided to exclude those miRNAs described 
as influenced by hemolysis in 3 or more of the relevant 
independent studies reporting hemolysis-induced miRNA 
dysregulation [56–63]. Accordingly, five miRNAs listed 
in Table 1 were excluded from possible clinical use: 
miR-486, miR-21, miR-21-5p, miR-126, miR-15b (see 
Supplementary Table 2). Among all miRNAs listed in 
Table 1 and considered unaffected by hemolysis, only 
miR-223, miR-20a, miR-448 and miR-145 displayed AUC 
value > 0.80 and sensitivity > 80% as stage I-II NSCLC 
biomarkers in at least one study. Moreover, miR-628-3p, 
miR-29c, miR-210 and miR-1244, despite low sensitivity 
and modest AUC value, showed specificity > 90% in at 
least one study. For these two sets of miRNAs, highly 
sensitive and highly specific respectively, the diagnostic 
accuracy data are summarized in Table 2. The seven 
studies analyzing these miRNAs [44, 46, 48, 50–53] are 
of medium overall quality according to the QUADAS-2 
checklist; they included 649 NSCLC patients (median, 
87 patients per study), predominantly smokers (62%) and 
represent 58% of the 1110 patients evaluated overall in the 
20 selected studies. The miRNAs shown in Table 2 have 
important biological functions related to tumorigenesis; 
although the analysis of these functions is beyond the 
purpose of this review, they are briefly described in 
Supplementary File 1.
miRNA panels
In the 20 selected studies, 12 miRNA panels 
featuring high sensitivity (> 80%) and/or high AUC (> 
0.80) as stage I-II NSCLC biomarkers were reported 
(Table 3). Five of these panels showed AUC> 0.90 and 
seven had AUC between 0.80 and 0.90; however some 
panels included miRNAs documented to be influenced by 
hemolysis (Table 3). 
Table 4 illustrates miRNAs that were described 
(either individually or within miRNA panels) as 
biomarkers of stage I-II NSCLC in more than one of the 
selected studies.
miRNAs and NSCLC subtypes
None of the 20 studies included in this review 
separately evaluated miRNA signatures in SCC or AC. 
However, 11 of the 20 selected studies evaluated the 
performance of circulating miRNAs in distinguishing 
NSCLC subtypes, and the investigated individual miRNAs 
and miRNA panels completely differed across the studies. 
As summarized in Table 5, the proposed miRNA signatures 
revealed: greater accuracy in identifying SCC than AC in 
7 studies [26, 29, 41, 46, 48, 49, 53]; similar accuracy 
in 2 studies [44, 54]; higher sensitivity for diagnosing 
AC in one study [30]. Wang et al. [50] reported that 
circulating levels of miR-425-3p and miR-628-3p were 
significantly higher in AC than SCC, while miR-532 was 
significantly lower in AC than SCC (Table 5). The AUCs 
for the miRNAs proposed as subtype-specific biomarkers 
were reported only in 4 studies [26, 48, 53, 54]. Altogether 
these findings show no consistent alterations of circulating 
miRNAs that may more accurately identify AC or SCC. 
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Table 1: Sensitivity, specificity and AUC of the 27 individual miRNAs described in the selected 
studies
miRNA Reference N Sensitivity (%) Specificity (%) AUC
223
Geng et al., 2014 [48] 186 87.0 86.0 0.94
Zhang et al, 2017 [51] 172 69.8 84.3 0.81
486* Li et al., 2015 [43] 22 91.0 82.0 0.93
20a
Geng et al., 2014 [48] 186 83.0 81.0 0.89
Zhang et al, 2017 [51] 172 79.8 88.0 089
448 Powrozek et al., 2016 [46] 114 85.0 77.0 0.89
21*
Sun et al., 2016 [55] 82 -- -- 0.88
Zhang et al, 2017 [51] 172 77.5 85.5 0.84
Geng et al., 2014 [48] 186 67.0 68.0 0.77
21-5p* Ma et al., 2013 [28] 74 -- -- 0.79
145
Zhang et al, 2017 [51] 172 80.6 89.2 0.89
Geng et al., 2014 [48] 186 70.0 68.0 0.77
141 Nadal et al., 2015 [45] 135 -- -- 0.88
193b Nadal et al., 2015 [45] 135 -- -- 0.86
200b Nadal et al., 2015 [45] 135 -- -- 0.85
126* Zhu et al., 2016 [52] 127 62.1 97.5 0.85
301 Nadal et al., 2015 [45] 135 -- -- 0.84
328 Ulivi et al., 2013 [49] 78 -- -- 0.82
4478 Powrozek et al., 2016 [46] 114 75.0 68.4 0.82
125b
Shi et al., 2017 [41] 210 30.4 83.9$ 0.81$
Yuxia et al., 2012 [42] 186 96.1 38.2 0.66
1244 Wang W et al., 2016 [53] 69 53.8 100.0 0.80
182 Zhu et al., 2016 [52] 127 67.8 85.0 0.78
425-3p Wang Y et al., 2016 [50] 173 67.1 68.1 0.73
628-3p Wang Y et al., 2016 [50] 173 42.7 91.2 0.73
29c Zhu et al., 2014 [44] 84 50.0 95.8 0.73
429 Zhu et al., 2014 [44] 84 94.4 41.7 0.72
22 Shi et al., 2017 [41] 210 43.5 86.3$ 0.72$
335-3p Ma et al., 2013 [28] 74 -- -- 0.71
532 Wang Y et al., 2016 [50] 173 53.7 80.2 0.66
210 Zhu et al., 2016 [52]       127 35.6 100.0 0.65
183 Zhu et al., 2016 [52] 127 41.4 82.5 0.64
15b* Shi et al., 2017 [41] 210 41.3 82.4$ 0.62$
N: sample size.
*asterisk denotes miRNA influenced by hemolysis; miRNA was considered hemolysis-influenced when documented in three 
or more relevant independent studies reporting hemolysis-induced miRNA dysregulation (see Supplementary Table 2). 
miRNAs shown in bold are those uninfluenced by hemolysis (see Additional Table 2) and with high sensitivity (> 80%) and 
high AUC (> 0.80) reported in at least one study shown in Reference column. 
miRNAs shown in bold underlined are those uninfluenced by hemolysis (see Additional Table 2) and with high specificity 
(> 90%) reported in at least one study shown in Reference column.
$Data are calculated among the total sample, that includes advanced stages (III and IV).
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Proposal of a two-step screening with miRNAs 
Based on the critique of the reviewed studies, we 
propose a model for screening of stage I-II NSCLC, using 
the two above indicated sets of individual miRNAs with 
the highest sensitivity/specificity (Table 2), that were 
selected as detailed in the Methods section. Panels of 
miRNAs were arbitrarily excluded from this model as 
the AUC or specificity data were based on the panels, and 
to simplify its possible clinical application. Accordingly, 
screening with miRNAs should be carried out in two steps. 
The four miRNAs with high sensitivity (miR-223, miR-
20a, miR-448 and miR-145) should be used for the first 
screening step (Test 1), and the four miRNAs with high 
specificity (miR-628-3p, miR-29c, miR-210 and miR-
1224) for the second step (Test 2). In this model the two 
panels of miRNAs are combined in series, and Test 2 is run 
only if Test 1 is positive, as described in Supplementary 
File 2. 
The final estimated performance of these miRNAs 
for the two-step screening of serum samples is overall 
sensitivity of 91.6% and overall specificity of 93.4%. The 
selected two sets of miRNAs with highest sensitivity/
specificity are intended for preliminary screening of the 
general population at high risk of lung cancer, dominated 
by smokers. Subjects positive to miRNA screening should 
be offered low-dose CT-screening, thus possibly reducing 
the logistic/economic burden and harms of upfront CT-
screening [12,14].
DISCUSSION 
Diagnosing lung cancer at an early stage is a 
major clinical concern that in recent years has stimulated 
extensive research on non-invasive screening methods, 
including miRNAs as lung cancer biomarkers in 
circulating body fluids. Dysregulated miRNA profiles 
in cell-free blood were shown to indicate the presence 
of lung cancer many months ahead of the occurrence of 
symptoms [64], and even before the disease was detected 
by CT screening [26, 65]. Therefore, miRNAs are 
potentially interesting biomarkers for screening of lung 
cancer [66]. According to “Medline Trend”, the number 
of publications on the topic “miRNA and NSCLC” has 
dramatically increased in the last 10 years, however the 
plethora of circulating miRNA profiles proposed as lung 
cancer signatures are inconsistent. Six systematic reviews 
[34–37, 39, 40] have summarized the main findings of 
these studies, but have failed to clearly identify circulating 
miRNAs possessing high proficiency specifically for the 
diagnosis of stage I-II NSCLCs, which are the cancers 
potentially amenable to radical cure. Considering 
that miRNA signatures of early and late lung cancer 
stages frequently differ [50, 64, 67–69], we exclusively 
reviewed papers reporting miRNAs biomarkers of stage 
I-II NSCLC. We focused on miRNA molecules of high 
diagnostic accuracy and whose measurement is scarcely 
influenced by hemolysis. Among the initially retrieved 
1712 papers fulfilling the search criteria, we only found 
20 studies clearly reporting quantitative data on miRNA 
diagnostic proficiency specifically for stage I-II NSCLC. 
Our review confirms the variability of miRNAs proposed 
by many authors as lung cancer signatures. Notably, there 
were only 18 miRNAs identified as biomarkers of stage 
I-II NSCLC in more than one published paper (Table 4). 
For the 20 selected studies we highlighted 
demographics, clinicopathological characteristics and 
smoking habit of patients and controls; moreover, we 
evaluated the main pre-analytical and analytical variables 
known to influence circulating miRNA levels. Notably, the 
training set in the selected studies consisted of a median 
of only 56 NSCLC patients, meaning that the training 
sample frequently was of smaller size than that suggested 
by guidelines for studies of biomarkers for early detection 
of cancer [70]. Moreover, in some of the selected studies 
the training sample appears definitely undersized if one 
considers the rather low precision of miRNA assays [63] 
and the expected diversity of miRNA signatures due to 
Table 2: miRNAs with high sensitivity and high AUC (a), and miRNAs with high specificity (b). 
a) miRNAs with sensitivity > 80% and AUC > 0.80
miRNA Sensitivity (%) AUC Specificity (%) Reference
miR-223 87.0 0.94 86.0 Geng et al., 2014 [48]
miR-20a 83.0 0.89 81.0 Geng et al., 2014 [48]
miR-448 85.0 0.89 77.0 Powrozek et al., 2016 [46]
miR-145 80.6 0.89 89.2 Zhang et al., 2017 [51]
b) miRNAs with specificity > 90%
miRNA Sensitivity (%) AUC Specificity (%) Reference
miR-628-3p 42.7 0.73 91.2 Wang Y et al., 2016 [50]
miR-29c 50.0 0.73 95.8 Zhu et al., 2014 [44]
miR-210 35.6 0.65 100.0 Zhu et al., 2016 [52]
miR-1244 53.8 0.80 100.0 Wang W et al., 2016 [53]
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molecular heterogeneity of NSCLC subtypes [36, 71–74]. 
Population ethnicity has been suggested as a potential 
source of miRNA level variability and of inconsistent 
miRNA signatures of lung cancer [77]. However, Shen et 
al. found no association between changes in circulating 
miRNA levels and patient ethnic group (African-American 
or Caucasian) [43]. As regards gender and age, several 
papers have documented that these variables do not 
significantly impact on lung cancer miRNA signatures [30, 
44, 50, 75, 76].
The proportion of smokers varied among the studies 
and sometimes markedly differed between cases and 
controls within the same study. In 5 of the 20 papers, 
cigarette smoking data were not reported, an important 
lack of information because some circulating miRNAs are 
significantly dysregulated by smoking [34, 77, 78]. 
Across the 20 studies, the control groups were also 
very different. The majority of studies defined the control 
group as “healthy subjects” not otherwise specified, 
or “non-neoplastic subjects” based on medical history. 
Notably, the composition of control groups is a critical 
issue, because diseases of liver, heart, prostate and various 
other comorbidities in the control group may influence the 
diagnostic sensitivity and specificity of miRNA candidate 
Table 3: Sensitivity (Se), specificity (Sp) and AUC of miRNA panels described in the selected studies
miRNA Panel Reference N Se(%) Sp(%) AUC
 1 miR-141, miR-200b, miR-193b, miR-301 Nadal et al., 2015 [45] 135 N.R. N.R. 0,99
 21 24 miRNAs* Wozniak et al., 2015 [54] 121 N.R. N.R. 0,98
 2 bis2 24 miRNAs* Wozniak et al., 2015 [54] 149 N.R. N.R. 0,96
 3 miR-182, miR-183, miR-210, miR-126, 
CEA Zhu et al., 2016 [52] 127 88,5 92,5 0,98
 4 miR-532, miR-628-3p, miR-425-3p Wang Y. et al. 2016 [50] 173 91,5 97,8 0,97
 5 miR-448, miR-4478 Powrozek et al., 2016 [46] 114 90 76.3 0,90
 6 miR-145, miR-20a, miR-21, miR-223 Zhang et al., 2017 [51] 172 81,8 90,1 0,90
 7 34 miRNAs** Bianchi et al., 2011 [26] 52 59 90 0,89
 8 miR-125b, miR-200b, miR-34b, miR-203, 
miR-205, miR-429 Halvorsen et al., 2016 [47] 158 85 74 0,88
 9 miR-21-5p, miR-335-3p Ma et al., 2013 [28] 74 N.R. N.R. 0,86
101 12 miRNAs*** Sanfiorenzo et al., 2013 [29] 33 N.R. N.R. 0,85
10 bis2 12 miRNAs*** Sanfiorenzo et al., 2013 [29] 42 N.R. N.R. 0,81
11 miR-1254, miR-574-5p
Foss et al., 2011 [27] 53 73 71 0,75
122 mir-21, miR-126, miR-210, miR-486-5p
Shen et al., 2011 [30] 44 73,3 96,5 N.R.
12 bis1 mir-21, miR-126, miR-210, miR-486-5p Shen et al., 2011 [30] 44 86,7 96,5 N.R.
N: sample size.
N.R.: Not Reported.
Panels are listed in decreasing order of AUC value. The studies by Wozniak et al., Sanfiorenzo et al., Shen et al. [54, 29, 30], 
separately described findings in stage I2 and stage II1 non-small cell lung cancer.
*let-7c, miR-122, miR-182, miR193a-5p, miR-200c, miR-203, miR-218, miR-155, let-7b, miR-411, miR-450b-5p, miR-
485-3p, miR-519a, miR-642, miR-517b, miR-520f, miR-206, miR-566, miR-661, miR-340, miR-1243, miR-720, miR-543, 
miR-1267.
**miR-92a, miR-484, miR-486-5p, miR-328, miR-191, miR-376a, miR-342-3p, miR-331-3p, miR-30c, miR-28-5p, miR-98, 
miR-17, miR-26b, miR-374a, miR-30b, miR-26a, miR-142-3p, miR-103, miR-126, let-7a, let-7d, let-7b, miR-32, miR-133b, 
miR-566, mir-432, miR-223, miR-29a, miR-148a, miR-142-5p, miR-22, miR-148b, miR-140-5p, miR-139-5p.
***miR-155-5p, miR-20a-5p, miR-25-3p, miR-296-5p, miR-191-5p, miR-126-3p, miR-223-3p, miR-152-3p, miR-145-5p, 
miR-199a-5p, miR-24-3p, and let-7f-5p.
miRNAs influenced by hemolysis are indicated in italics; miRNA was considered hemolysis-influenced if influence 
was documented in three or more relevant independent studies reporting hemolysis-induced miRNA dysregulation (see 
Supplementary Table 2).
miRNAs indicated in bold are also accurate individual predictors, included in Table 2.
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biomarkers [79–81]. Only 4 of 20 studies subdivided 
control patients by comorbidity: benign lung nodules, 
COPD, noncancerous disease, smoker [29, 48, 50, 52]. 
It is debated if “controls” for lung cancer patients should 
be age-matched “healthy subjects” or subjects with a 
history of smoking, and whether COPD patients should 
be included as controls. Because levels of miRNA relevant 
for lung cancer may be altered in smokers [34, 77] and 
in COPD patients [82–84], the control group composition 
in terms of smoking pack/years and COPD prevalence 
may bias the accuracy of miRNAs selected as lung cancer 
biomarkers. In order to avoid a COPD-based miRNA 
signature, in the studies by Sanfiorenzo et al. [29] and 
Halvorsen et al. [47], non-neoplastic COPD patients were 
used as controls. 
Elegant experimental studies have shown that 
miRNAs derived from cancer tissue can enter the 
circulation [24]. Moreover, in lung cancer patients several 
overexpressed circulating miRNAs (miR-21, miR-24, 
miR-145, miR-20a, miR-223, miR-486, miR-574-5p, 
miR-1825, miR-205, miR-19a, miR-19-b, miR-30b) 
were generally reduced a few days after tumor resection, 
strongly suggesting that these molecules are of tumor 
origin or tumor-induced [43, 51, 75, 85, 86]. It is therefore 
reasonable to assume that at least some of the aberrantly 
expressed miRNAs in the blood of lung cancer patients 
are genuine biomarkers of the tumor. The measurement of 
circulating miRNAs faces numerous technical challenges 
and may be biased by multiple factors, partly explaining 
the inconsistency of published miRNA profiles of lung 
cancer [51]. Because several circulating miRNAs are 
blood-cell derived [56, 59–62, 87], spurious miRNA level 
dysregulations that may result from platelet contamination 
and red blood cell lysis in plasma/serum samples are a 
major concern. Our review suggests that potential 
bias of hemolysis on miRNA levels has often been 
underestimated, as only in 2 of the 20 reviewed studies 
was hemolysis of specimens ruled out [29, 54]. In order to 
avoid spurious effects of undetected hemolysis of samples, 
in agreement with Pritchard and collaborators [88], we 
suggest that miRNAs influenced by hemolysis should 
preferably not be used as NSCLC biomarkers. 
For analysis of circulating miRNAs, both serum and 
plasma are acceptable sample types, and a good correlation 
between serum and plasma miRNA determinations has 
been documented [89]. However, serum and plasma 
Table 4: miRNAs indicated as stage I-II NSCLC biomarkers in more than one of the selected 
studies
miRNA Number of 
studiesa 
References
miR-21 4 Sun et al., 2016 [55]; Zhang et al., 2017 [51]; Geng et al., 2014 [48]; Shen et al., 2011 [30]* 
miR-223 4 Zhang et al., 2017 [51]; Geng et al., 2014 [48]; Sanfiorenzo et al., 2013 [29]*; Bianchi et 
al., 2011 [26]*
miR-126 4 Zhu et al., 2016 [52]; Sanfiorenzo et al., 2013 [29]*; Shen et al., 2011 [30]*; Bianchi et al., 
2011 [26]*
miR-20a 3 Zhang et al., 2017 [51]; Geng et al., 2014 [48]; Sanfiorenzo et al., 2013 [29]* 
miR-145 3 Zhang et al., 2017 [51]; Geng et al., 2014 [48]; Sanfiorenzo et al., 2013 [29]* 
miR-125b 3 Shi et al., 2017 [41]; Halvorsen et al., 2016 [47]*; Yuxia et al., 2012 [52] 
miR-486 3 Li et al., 2015 [77]; Shen et al., 2011 [30]*; Bianchi et al., 2011 [26]*
miR-155 3 Geng et al., 2014 [48]; Wozniak et al., 2015 [54]*; Sanfiorenzo et al., 2013 [29]* 
miR-200b 2 Halvorsen et al., 2016 [47]*; Nadal et al., 2015 [45]* 
miR-328 2 Ulivi et al., 2013 [49]; Bianchi et al., 2011 [26]*
miR-182 2 Zhu et al., 2016 [52]; Wozniak et al., 2015 [54]*
miR-429 2 Halvorsen et al., 2016 [47]*; Zhu et al., 2014 [44]
miR-210 2 Zhu et al., 2016 [52]; Shen et al., 2011 [30]*
miR-22 2 Shi et al., 2017 [41]; Bianchi et al., 2011 [26]*
miR-203 2 Halvorsen et al., 2016 [47]*; Wozniak et al., 2015 [54]*
let-7b 2 Wozniak et al., 2015 [54]*; Bianchi et al., 2011 [26]*
miR-566 2 Wozniak et al., 2015 [54]*; Bianchi et al., 2011 [26]*
miR-191 2 Sanfiorenzo et al., 2013 [29]*; Bianchi et al., 2011 [26]*
anumber of reviewed studies indicating the specified miRNA as stage I-II NSCLC biomarker.
*Asterisk denotes panel including the specified miRNA.
miRNAs indicated in bold are included in our two-step screening (Table 2).
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Table 5: Characteristics of the 11 included studies evaluating the performance of circulating 
miRNAs in distinguishing NSCLC subtypes 
Reference Year Sample 
ethnicity
Sample Sizea NSCLCd 
Stage
miRNAs examined AUCe in discriminating 
NSCLC subtype from 
controls for the examined 
miRNAs
Comments on miRNA performance
Ptb Cc ACf (n) SCCg (n)
Bianchi et al. [26] 2011 Caucasian 22h 30 I Panel of 34 
miRNAs*
(n = 22)
0.85
 (n = 12)
0.94h
The panel distinguished better SCCs than ACs from controls; 
however, the SCCs were stage II-IV cases. Sample size was small.
Geng et al. [48] 2014 Asian 126 60 I-II 5 miRNAs:
miR-20a  
miR-223  
miR-21  
miR-155   
miR-145
(n = 45)
0.90
0.91
0.63
0.93
0.77
(n = 64)
0.98
0.98
0.97
0.96
0.97
All 5 miRNAs differentiated NSCLC from controls with greater 
accuracy in SCCs. 17 cases had histology other than AC or SCC.
Powrozek et al. 
[46]
2016 Caucasian 29i 85 I-II 2 individual 
miRNAs:
miR-448, miR-
4478; combination 
of both miRNAs
(n = 30)
NAl
(n = 35)
NA
Both miRNAs overexpressed in NSCLC plasma samples relative 
to control. miR-4478 expression was higher in SCC than in AC 
patients (p < 0.043).  Analysis of miRNA performance included 
36 cases with stage >II.
Sanfiorenzo et al. 
[29]
2013 NA 35i 20 I-II Panel of 12 
miRNAs**
(n = 27)
NA
(n = 25)
NA
Panel distinguished NSCLC patients from controls (AUC=0.81). 
In SCC compared to AC, higher plasma levels of miR-20a-5p 
(p = 0.034) and miR-25-3p (p = 0.013), along with lower levels 
of miR-191-5p (p = 0.008) were found. Analysis of miRNA 
performance included 17 cases with stage >II.
Shen et al. [30] 2011 African 
American, 
Caucasian
30i 29 I-II miR-21, 
miR-126, miR-210, 
miR-486-5p
(n = 24)
NA
(n = 34)
NA
Diagnostic sensitivity of the composite panel in distinguishing 
stage I NSCLC from controls was 73.3%. Analysis of miRNA 
performance in diagnosing subtypes included 28 cases with stage 
>II and showed higher sensitivity for diagnosing ACs (91.7%) 
than SCCs (82.3%) (p < 0.05).
Shi et al. [41] 2017 NA 46i 45 I-II miR-22, 
miR-125b, miR-15b
(n = 69)
NA
(n = 51)
NA
Serum levels of the three miRNAs significantly altered in NSCLC 
cases compared to controls. Diagnostic sensitivity of miR-125b 
was significantly higher for ACs than SCCs (p = 0.021). Analysis 
of miRNA performance included 74 cases with stage >II.
Ulivi et al. [49] 2013 Caucasian 54i 24 I-II miR-328  (n = 63)
NA
(n = 22)
NA
miR-328 discriminated well between stage I-II NSCLC and 
controls (AUC = 0.82). Analysis of miRNA performance 
for subtypes, conducted in 86 NSCLCs (63 ACs; 22 SCC; 
1 sarcomatoid), 32 of which were in stage > II, indicated 
significantly higher expression of miR-423 in SCCs than in ACs. 
The miRNA analyses were performed in whole blood specimens. 
Wang Y. et al. 
[50]
2016 Asian 82 91 I-II miR-532, miR-628, 
miR-425-3p
(n = 40)
NA
(n = 39)
NA
Combination of the three miRNAs discriminated well NSCLC 
from control plasma samples (AUC = 0.97). Evaluation of 
miRNA performance was conducted in 40 ACs and 39 SCCs. 
Plasma levels of miR-425-3p (p = 0.04) and of miR-628-3p 
(p = 0.015) were significantly higher in AC than SCC. miR-532 
was significantly lower in AC than SCC (p < 0.001).
Wang W. et al. 
[53]
2016 NA 54i 15 I-II miR-1244 (n = 26)
0.79
(n = 17)
0.85
For miR-1244 the AUC was higher in SCC than AC. AUC was 
assessed on serum samples of 43 NSCLCs (26 ACs; 17 SCCs), 17 
of which were in stage > II. 
Wozniak et al. 
[54]
2015 Caucasian 70i 100 I-II Panel of 24 
miRNAs***
(n, NA)
0.94
(n, NA)
0.96
Panel showed similar accuracy for distinguishing AC and SCC 
from controls. AUC for the panel was assessed in 70 NSCLCs 
[a sub-cohort of 100 NSCLCs (35 ACs; 65 SCCs), 30 of which 
were in stage >II]. 
Zhu et al. [44] 2014 Asian 36i 48 I miR-29c,
miR-93,
miR-429
(n =34)
NA
(n = 36)
NA
The evaluation of 70 NSCLCs (34 ACs; 36 SCC), 34 of which 
were in stage II–IV, showed non-significant difference of serum 
miR-29c (p = 0.232) and miR-429 (p = 0.811) between AC and 
SCC. 
aThe sample refers to stage I and II NSCLC.
bPt=Patients; cC=Controls.
dNSCLC: non-small cell lung cancer.
eAUC=area under the curve.
fAC: adenocarcinoma.
gSCC=squamous cell carcinoma.
hSCCs were 12 additional cases with stage II-IV disease.
iAnalysis of miRNA performance included also cases with stage > II.
lNA: Not available.
*miR-92a, miR-484, miR-486-5p, miR-328, miR-191, miR-376a, miR-342-3p, miR-331-3p, miR-30c, miR-28-5p, miR-98, miR-17, miR-26b, miR-374a, miR-30b, miR-26a, 
miR-142-3p, miR-103, miR-126, let-7a, let-7d, let-7b, miR-32, miR-133b, miR-566.
**miR-155-5p, miR-20a-5p, miR-25-3p, miR-296-5p, miR-191-5p, miR-126-3p, miR-223-3p, miR-152-3p, miR-145-5p, miR-199a-5p, miR-24-3p, and let-7f-5p.
***let-7c, miR-122, miR-182, miR-193a-5p, miR-200c, miR-203, miR218, miR-155, let-7b, miR-411, miR-450b-5p, miR-485-3p, miR-519a, miR-642, miR-517b, miR-520f, 
miR-206, miR-566, miR-661, miR-340, miR-1241, miR-720, miR-543, miR-1267.
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determinations cannot be automatically interchanged, 
because differences in specimen preparation and/or 
measurement platform are known to influence the results. 
As an example, in normal subjects miR-15b and miR-16 
showed higher concentrations in plasma relative to serum 
in one study [63], while the concentration of the same two 
miRNAs was higher in serum relative to plasma in another 
independent study using a different platform [90]. 
 It is currently debated whether serum or plasma 
should be used for circulating miRNAs determination; 
mirroring this uncertainty, 10 of the 20 selected studies 
were performed with serum samples and 9 with plasma. 
Serum has not been generically recommended over plasma 
as a sample type [87]; however, serum has less platelet 
contamination than plasma, and this may decrease bias 
in miRNA determination [63]. Regarding the method for 
miRNA quantification, all the reviewed studies except 
that of Ma et al. [28] used qPCR platform and performed 
normalization of results predominantly with endogenous 
miR-16 and U6, or with spike-ins. The normalization 
step is likely to contribute to the scarce reproducibility 
of miRNA determinations, as reported by others [33]. 
Normalization with miR-16 can be criticized because this 
miRNA has been described as a lung cancer biomarker 
itself [91–93]. U6, a small nuclear RNA, was shown 
to fluctuate markedly across samples [94], and such 
variability may contribute to inconsistency of miRNA 
findings. For miRNA measurement Ma et al. [28] used 
ddPCR, a recently introduced technique reported to be 
advantageous over qPCR (greater precision; no need to 
normalize results; higher sensitivity to low-level miRNA 
expression) [28, 95]. Altogether, these considerations 
underscore the importance of knowing the miRNA 
quantification procedure details, to allow reproducibility 
of methods and external validation of studies. 
Distinguishing between the AC and SCC lung cancer 
subtypes on the basis of specific circulating miRNAs’ 
aberrant expression may provide important information, 
relevant both for understanding the subtypes’ pathogenesis 
and for tailored selection of cytotoxic chemotherapy 
in NSCLC without a driver mutation [96]. Moreover, 
although histology and immunohistochemistry (IHC) 
currently are the gold standards for NSCLC diagnosis, 
the subtype classification of difficult cases (scarce 
biopsy sample; hazardous/difficult biopsy; uncertain 
IHC) could be facilitated if subtype-specific circulating 
miRNA signatures were available. Few studies have 
been conducted in stage I-II NSCLC patients to identify 
circulating miRNA profiles than may be more accurate 
for either AC or SCC. In our systematic review we only 
found 11 studies that separately analyzed AC and SCC 
cases [26, 29, 30, 41, 44, 46, 48–50, 53, 54], and none of 
these provided convincing evidence that a specific miRNA 
signature exists for each of the two subtypes. A notable 
methodological weakness in 9 of these 11 studies [26, 29, 
30, 41, 44, 46, 48–50, 53, 54] is the inclusion of many 
lung cancers in advanced stage (stage > II) in the subtype 
analysis, likely to compensate for small sample size of 
the AC and SCC sub-cohorts. Of note, Bianchi et al. [26], 
Geng et al. [48], Powrozek et al. [46], Sanfiorenzo et al. 
[29], Shi et al. [41], Ulivi et al. [49] and Wang et al. [53] 
proposed very different miRNA signatures of early stage 
NSCLC, yet all these signatures better differentiated SCC 
than AC from controls. Altogether, the available data are 
insufficient to define serum/plasma miRNA profiles that 
may reliably discriminate between AC and SCC in stage 
I-II lung cancer.
Strengths and limitations 
A strength of this review is the critique focused 
on circulating miRNA biomarkers of stage I-II NSCLC, 
the disease stages often amenable to radical cure and 
for which non-invasive screening by miRNAs may be 
proposed. Another strength is the assessment of factors 
potentially influencing miRNA levels and the evaluation 
of miRNAs’ accuracy as stage I-II NSCLC biomarkers by 
quantitative data (sensitivity, specificity, AUC).
This review has important limitations. First, miRNA 
signatures of NSCLC may be biased by pre-analytical 
and analytical factors, and by clinicopathological features 
of patients and controls. Second, in many of the selected 
papers the validation sample was relatively small (median, 
56 patients), with limited power to correctly identify the 
miRNA signature of stage I-II NSCLC. Third, lack of 
methodological details in some studies prevented thorough 
evaluation of the quality of methodology used. Data on 
comorbidities, some of which may affect miRNA expression 
[79–81], were not provided in some papers. Accordingly, at 
QUADAS-2, “patient selection” and “index test” resulted 
the most critical domains, and overall the studies were only 
of medium quality. Another limitation is that the miRNA 
panels for our two-step model of screening were obtained 
from studies where only the majority of lung cancer patients 
(62%) were smokers, while screening for lung cancer is 
currently recommended exclusively in smokers (11). In this 
review, we aimed to identify circulating individual miRNAs 
with sensitivity > 80% and AUC > 0.80 as biomarkers of 
stage I-II NSCLC, for possible clinical application as non-
invasive screening tool. Based on the reviewed studies, 
we found four individual miRNAs that fulfilled these 
criteria: miR-223, miR-20a, miR-448 and miR-145; four 
other miRNAs showed very high specificity (> 90%): miR-
628-3p, miR-29c, miR-210 and miR-1244. Among factors 
potentially affecting circulating miRNAs, the only two that 
were considered for miRNAs selection were the stage of 
NSCLC (all studies were stages I-II) and the impact of 
hemolysis (miRNAs potentially affected by hemolysis 
were excluded). Other factors, such as smoking habits, age, 
ethnicity, methodological issues of RNA extraction, could 
not be controlled because they varied widely among the 
selected studies.
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Screening for lung cancer with circulating miRNAs, 
preliminary to CT-screening, is a minimally invasive and 
safe blood test that may offer several advantages over 
upfront CT-screening: reduction of number of CT-screens 
(to be performed only in miRNA screening-positive 
individuals) and of radiation risk; decrease of false-
positive CT-screening rate and consequent reduction of 
complications and costs from futile lung biopsies (12,14). 
We have proposed a two-step model of miRNA screening 
for stage I-II NSCLC, based on the measurement of the 
serum level of the above indicated selected miRNAs 
(Table 2): the panel of four miRNAs with high sensitivity 
should be used for the first screening step, and the panel 
with high specificity for the second step. Based on our 
model, for the two miRNA panels combined in series for 
screening of serum samples the estimated performance 
is overall sensitivity of 91.6% and overall specificity of 
93.4%. The estimated diagnostic accuracy of the proposed 
model is similar to that of the 12 miRNA panels found in 
the selected papers (Table 3), most of which featured high 
sensitivity (> 80%) and/or high AUC (> 0.80) as stage I-II 
NSCLC biomarkers. However, several of these panels 
contain miRNAs that are not ideal biomarkers; as Table 
3 shows, 6 of the 12 panels included miRNAs influenced 
by hemolysis. Moreover, Nadal et al. and Wozniak et 
al. provided no sensitivity nor specificity data for their 
panels [45, 54] and the panels tested by Powrozek et al., 
Halvorsen et al., and Foss et al. showed modest specificity 
(76.3%, 74% and 71%, respectively) [27, 46, 47]. The 
panel proposed by Wang et al. featured high proficiency in 
diagnosing AC, without containing hemolysis-influenced 
miRNAs [50].
MATERIALS AND METHODS
Search strategy
A systematic review of the scientific literature was 
conducted using the following key words: [(NSCLC OR 
Non Small Cell Lung Cancer) AND (lung cancer) AND 
(miRNA OR MicroRNA) AND (diagnosis)]” on the search 
engines of the databases “Pubmed”, “Medline”, “Scopus”, 
“Embase” and “WOS”. The research was first performed 
on July 21st  2016 and results were regularly updated until 
April 12th 2017. Including criteria were: i) circulating 
miRNAs; ii) histologically/cytologically defined NSCLC 
stage I and/or II (studies of patients with NSCLC at any 
stage were included only if a sub-analysis for stage I-II was 
provided); iii) studies reporting quantitative data on the 
efficacy of specific miRNAs as tools for stage I-II NSCLC 
screening (sensitivity, specificity and/or AUC); iv) English 
language. Studies analyzing single miRNAs and/or panels 
of miRNAs were included. Duplicate publications were 
eliminated through the Mendeley software [97]. All 
articles of interest were then evaluated and screened 
for eligibility by two researchers, independently, and 
controversies were resolved by consensus. Bibliography 
of the selected papers was manually examined to retrieve 
further articles with eligibility criteria.
The protocol was registered at the international 
prospective register of systematic reviews (PROSPERO, 
ID: CRD42017056943). The PRISMA statement and 
the Cochrane Handbook for Diagnostic Test Accuracy 
Reviews were followed as reference protocol standards.
Data extraction 
From the eligible studies the following information 
was collected: a) author name, year and country where the 
study was performed; b) sociodemographic and clinical 
information on population under study (ethnicity, sample 
size, age, smoking status, comorbidity, NSCLC stage); c) 
individual miRNAs and/or miRNA panels under study; 
d) methodological issues regarding miRNAs extraction 
[type of specimen (plasma/serum/whole blood), hemolysis 
assessment, RNA isolation and measurements procedures]; 
e) quantitative data of diagnostic accuracy (sensitivity, 
specificity, AUC) for stage I-II NSCLC.
The papers then underwent rigorous critical 
evaluation, taking into account: i) quality of the study, 
assessed by the Quality Assessment of Diagnostic 
Accuracy Studies (QUADAS-2) checklist [98]; ii) factors 
identified as potentially affecting miRNA quantification 
(Table 6). Two investigators independently assessed the 
seven domains of the QUADAS-2. Any discrepancies 
were resolved through discussion. 
Selection of circulating miRNAs for a two-step 
screening preliminary to CT-screening 
Within studies with overall satisfactory quality by 
QUADAS-2, we identified individual miRNAs showing 
at least in one study high diagnostic proficiency as stage 
I-II NSCLC biomarkers (arbitrarily stated as sensitivity 
> 80% and AUC > 0.80, or specificity > 90%) and scarcely 
influenced by hemolysis according to the pertinent 
literature [56–63]. Altogether eight individual miRNAs 
revealed the aforementioned high diagnostic proficiency 
as stage I-II NSCLC biomarkers (miR-223, miR-20a, 
miR-448, miR-145, miR-628-3p, miR-29c, miR-210 and 
miR-1244; Table 2). These miRNAs with the highest 
sensitivity/specificity can be applied in a mathematical 
model, that we are here proposing, to estimate their 
overall sensitivity and specificity for stage I-II NSCLC 
screening. The model consists of a two-step screening 
test, first using the panel of selected circulating miRNAs 
with high sensitivity and high AUC, then the panel of 
selected miRNAs with high specificity, as illustrated in 
Supplementary File 2. We arbitrarily excluded miRNA 
panels from the model since the AUC or specificity data 
were based on the panels and not individual miRNAs, 
aiming to simplify possible clinical application of the 
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test. However, for comparison of our model’s diagnostic 
accuracy, the other miRNA panels included in the review 
are discussed.  
Statistical analysis
The proposed two-step model for estimating overall 
sensitivity and specificity of circulating miRNAs to be 
used for stage I-II NSCLC screening was developed using 
the formulas described in Supplementary File 2.
CONCLUSIONS
Several pre-analytical and analytical variables of 
circulating miRNA measurements, especially hemolysis 
of samples, may bias the accuracy of miRNAs as 
biomarkers of stage I-II NSCLC. Evidence-based data 
are insufficient to reach a robust conclusion as to which 
circulating miRNAs are the best biomarkers of early 
lung cancer, and also insufficient to define serum/plasma 
miRNA profiles that may reliably discriminate between 
AC and SCC.
Nevertheless, based on critical review of the 
literature, selected circulating miRNAs that are scarcely 
influenced by hemolysis could be tested for screening 
early lung cancer in smokers and former smokers. For 
our theoretical model of two-step screening for stage 
I-II NSCLC, first using a panel of miRNAs with high 
sensitivity and then a panel with high specificity, we 
estimated overall sensitivity of 91.6% and overall 
specificity of 93.4%. The circulating miRNAs we selected 
as potentially valuable biomarkers of early lung cancer 
based on this review, as well as those described by other 
authors, require validation in multiple independent studies 
before they can be proposed for clinical application. 
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Table 6: Factors potentially affecting circulating miRNA quantification in NSCLC patients
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Reverse transcription method
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NSCLC: non-small cell lung cancer.
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